Design and Synthesis of Organic Molecules for Anticancer Drug Development

References

[1] Anastas, P. T., & Warner, J. C. (1998). Green Chemistry: Theory and Practice. Oxford University Press.

[2] Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. https://doi.org/10.1038/nrg.2016.86

[3] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492

[4] Claridge, T. D. W. (2016). High-Resolution NMR Techniques in Organic Chemistry (3rd ed.). Elsevier.

[5] DeVita, V. T., & Rosenberg, S. A. (2012). Two hundred years of cancer research. New England Journal of Medicine, 366(23), 2207–2214. https://doi.org/10.1056/NEJMra1204479

[6] Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35(4), 495–516. https://doi.org/10.1080/01926230701320337

[7] Ferrara, N. (2004). Vascular endothelial growth factor as a target for anticancer therapy. Oncologist, 9(Suppl. 1), 2–10. https://doi.org/10.1634/theoncologist.9-90001-2

[8] Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual Review of Medicine, 53, 615–627. https://doi.org/10.1146/annurev.med.53.082901.103929

[9] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

[10] Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x

[11] Hurley, L. H. (2002). DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer, 2, 188–200. https://doi.org/10.1038/nrc749

[12] Jampilek, J. (2019). Heterocyclic scaffolds in anticancer drug development. Molecules, 24(2), 383. https://doi.org/10.3390/molecules24020383

[13] Kaushik, N. K., Kaushik, N., Attri, P., Kumar, N., Kim, C. H., Verma, A. K., & Choi, E. H. (2013). Biomedical importance of indoles. Molecules, 18(6), 6620–6662. https://doi.org/10.3390/molecules18066620

[14] Katzung, B. G., Masters, S. B., & Trevor, A. J. (2018). Basic & Clinical Pharmacology (14th ed.). McGraw-Hill Education.

[15] Lavecchia, A. (2015). Machine-learning approaches in drug discovery: Methods and applications. Drug Discovery Today, 20(3), 318–331. https://doi.org/10.1016/j.drudis.2014.10.012

[16] Lombardino, J. G., & Lowe, J. A. (2004). The role of the medicinal chemist in drug discovery—Then and now. Nature Reviews Drug Discovery, 3, 853–862. https://doi.org/10.1038/nrd1523

[17] Luo, J., Solimini, N. L., & Elledge, S. J. (2009). Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell, 136(5), 823–837. https://doi.org/10.1016/j.cell.2009.02.024

[18] Mishra, R., Tomar, I., Singhal, S., & Shrivastava, S. K. (2017). Recent advances in anticancer activity of heterocyclic compounds. European Journal of Medicinal Chemistry, 132, 53–75.

[19] Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1–2), 55–63. https://doi.org/10.1016/0022-1759(83)90303-4

[20] Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products, 79(3), 629–661. https://doi.org/10.1021/acs.jnatprod.5b01055

[21] Patrick, G. L. (2017). An Introduction to Medicinal Chemistry (6th ed.). Oxford University Press.

[22] Pfeffer, C. M., & Singh, A. T. K. (2018). Apoptosis: A target for anticancer therapy. International Journal of Molecular Sciences, 19(2), 448. https://doi.org/10.3390/ijms19020448

[23] Roskoski, R. (2016). Classification of small molecule protein kinase inhibitors based upon the structures of their drug–enzyme complexes. Pharmacological Research, 103, 26–48. https://doi.org/10.1016/j.phrs.2015.10.013

[24] Sawyers, C. L. (2004). Will cancer be cured? New England Journal of Medicine, 351(21), 2239–2241. https://doi.org/10.1056/NEJMp048265

[25] Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010). Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Letters, 10(9), 3223–3230. https://doi.org/10.1021/nl102184c

[26] Silverstein, R. M., Webster, F. X., Kiemle, D. J., & Bryce, D. L. (2014). Spectrometric Identification of Organic Compounds (8th ed.). Wiley.

[27] Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334–395. https://doi.org/10.1124/pr.112.007336

[28] Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Molecular Informatics, 29(6–7), 476–488. https://doi.org/10.1002/minf.201000061

[29] Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546–1558. https://doi.org/10.1126/science.1235122

[30] Vousden, K. H., & Prives, C. (2009). Blinded by the light: The growing complexity of p53. Cell, 137(3), 413–431. https://doi.org/10.1016/j.cell.2009.04.037

[31] Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 9, 28–39. https://doi.org/10.1038/nrc2559

@article{1722987,
      author = {Dr. K. S. Lamani},
      title = {Design and Synthesis of Organic Molecules for Anticancer Drug Development},
      journal = {Iconic Research And Engineering Journals},
      year = {2019},
      volume = {2},
      number = {8},
      pages = {375-384},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722987.pdf},
      abstract = {Cancer is still one of the largest global health burdens due to the complex biology behind the process, uncontrolled proliferation of cells and mutations, as well as continuous and insistent needs to develop novel effective anticancer agents although established anticancer drugs made some notable success in cancer treatment. Many established chemotherapy drugs suffer from serious disadvantages like resistance development, lack of specificity toward tumor cell and normal cell, toxicity related with dosage, undesirable adverse effects and relatively low therapeutic index, therefore creating an imperative need for novel drugs and chemical entities with better physicochemical and pharmacokinetic properties. Organic molecules form a quintessential backbone for the development of medicinal chemistry today with its potential for structural variation, ability to participate in chemical transformations and to interact with particular cellular targets which in turn enable them as valuable molecular species to design selective anticancer agents, affecting the cellular pathways which were reported to be crucial in cancer promotion, survival and pathogenesis. This conceptual research article aims to present the systematic process of design and synthesis of novel organic molecules which has the potential to be used as novel anticancer agent using rational molecular design approaches, functionalization/modification of privileged structure and advanced organic synthesis approaches towards the identification of molecular features corresponding to an enhanced activity, selectivity and druglike properties. The presented strategy to design and synthesis novel cancer static entities comprises structural optimization via derivatization, heterocyclic moiety inclusion and molecular architecture modification as strategy to explore relation between molecular structure and anti-cancer activity and to identify beneficial groups for anti-cancer activity; The developed molecules were hypothetically suggested to have their structural elucidation using various Spectroscopic characterizations such as fourier transform infrared spectrum, Nuclear Magnetic Resonance spectrum and Mass spectroscopy while potential interaction with tumor related proteins was predicted with computational approach using docking; Moreover the molecular models were designed by applying a knowledge of relation between molecular structure and anti-cancer activity, which includes molecular modeling and QSAR prediction as well as ADMET analysis to have an idea of interactions between target molecules and predicted drug molecules and drug-like characters which is useful to identify promising lead compounds before the biological assay.},
      keywords = {Anticancer Drug Development, Organic Molecules, Medicinal Chemistry, Rational Molecular Design, Organic Synthesis, Structure–Activity Relationship (SAR)},
      month = {February},
      doi = {https://doi.org/10.64388/IREV2I8-1722987}
  }